EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE [EFFICACIA E SICUREZZA DEL NERIDRONATO INTRAMUSCOLARE NEL TRATTAMENTO DELL OSTEOPOROSI IN PAZIENTI PARKINSONIANI]

Trial Profile

EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE [EFFICACIA E SICUREZZA DEL NERIDRONATO INTRAMUSCOLARE NEL TRATTAMENTO DELL OSTEOPOROSI IN PAZIENTI PARKINSONIANI]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2014

At a glance

  • Drugs Neridronic acid (Primary)
  • Indications Hip fracture; Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top